Some day-after thoughts on Bristol Myers Squibb acquiring Mirati Therapeutics fr...
The FDA rejected an Alnylam therapy for an increasingly prevalent heart disease,...
Taking aim at a major killer, the well-funded startup Delfi Diagnostics launches...
STAT spoke with the global head of Boehringer Ingelheim's innovation unit, about...
Amgen has acquired Ireland-based biotechnology company Horizon Therapeutics in ...
The US is known for having higher list prices for drugs than other high-income ...
The US Food and Drug Administration (FDA) has approved an intravenous (IV) vers...
Limmatech, the GSK spinout focusing on antimicrobial resistance, announced on M...
GSK and Chongqing Zhifei Biological Products (Zhifei) have signed an exclusive ...
In recent years, the US has made major strides in the treatment landscape for t...
Ultimovacs has received an orphan drug designation from the US Food and Drug Ad...
More than 20 companies working alongside the UK’s National Health Service (NHS)...
British biotech AstronauTx has completed a Series A funding round of £48m ($58....
Alnylam Pharmaceuticals has had to abandon its plans to pursue a label expansio...
Venture firm General Catalyst is creating a health-focused business spinout with...
The decision by Bristol Myers Squibb to buy MIrati for $4.8 billion reflects a r...
